Effects of insulin-like growth factor 1 on neutrophil and monocyte functions in normal and septic states

Journal of Parenteral and Enteral Nutrition

Volumn 22, Issue 3, 1998, Pages 127-135

  Balteskard, Lise ^a,b   Unneberg, Kjetil ^a   Halvorsen, Dag ^a   Hansen, John Bjarne ^a   Revhaug, Arthur ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE FUNCTION; MONOCYTE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; SEPSIS;

EID: 0031897780     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607198022003127     Document Type: Article

References (52)

1. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992
2. Natanson C, Hoffman WD, Suffredini AF, et al: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771-783, 1994
3. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986
4. Michie HR, Spriggs DR, Manogue KR, et al: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104:280-286, 1988
5. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355-357, 1987
6. Mullen PG, Windsor AC, Walsh CJ, et al: Tumor necrosis factor-alpha and interleukin-6 selectively regulate neutrophil function in vitro. J Surg Res 58:124-130, 1995
7. Zimmerman JJ, Ringer TV: Inflammatory host responses in sepsis. Crit Care Clin 8:163-189, 1992
8. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989
9. Rom WN, Basset P, Fells GA, et al: Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest 82:1685-1693, 1988
10. Petty HR, Francis JW, Boxer LA: Deficiency in immune complex uptake by chronic granulomatous disease neutrophils. J Cell Sci 90:425-432, 1988
11. Gabrilove JL, Jakubowski A: Biological effects and clinical applications of human colony-stimulating factors. Cancer Chemother Biol Response Modif 11:631-662, 1990
12. Baxter JB, Blalock JE, Weigent DA: Characterization of immunoreactive insulin-like growth factor-I from leukocytes and its regulation by growth hormone. Endocrinology 129:1727-1734, 1991
13. Johnson EW, Jones LA, Kozak RW: Expression and function of insulin-like growth factor receptors on anti-CD3-activated human T lymphocytes. J Immunol 148:63-71, 1992
14. Zhao X, McBride BW, Trouten Radford LM, et al: Specific insulin-like growth factor-I receptors on circulating bovine mononuclear cells. J Recept Res 12:117-129, 1992
15. Fu YK, Arkins S, Wang BS, et al: A novel role of growth hormone and insulin-like growth factor-I. Priming neutrophils for superoxide anion secretion. J Immunol 146:1602-1608, 1991
16. Edwards CK, Arkins S, Yunger LM, et al: The macrophage-activating properties of growth hormone. Cell Mol Neurobiol 12:499-510, 1992
17. Renier G, Clement I, Desfaits AC, et al: Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology 137:4611-4618, 1996
18. Fan J, Li YH, Bagby GJ, et al: Modulation of inflammation-induced changes in insulin-like growth factor (IGF)-I and IGF binding protein-1 by anti-TNF antibody. Shock 4:21-26, 1995
19. Clark R, Strasser J, McCabe S, et al: Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest 92:540-548, 1993
20. Schurmann A, Spencer GS, Berry CJ, et al: Evidence for suppression of immune function by insulin-like growth factor-1 in dwarf rats in vivo. Experientia 52:55-59, 1996
21. Murphy WJ, Durum SK, Anver MR, et al: Immunologic and hematologic effects of neuroendocrine hormones. Studies on DW/J dwarf mice. J Immunol 148:3799-3805, 1992
22. Cornell RP: Gut-derived endotoxin elicits hepatotrophic factor secretion for liver regeneration. Am J Physiol 249:R551-562, 1985
23. Elsasser TH, Caperna TJ, Rumsey TS: Endotoxin administration decreases plasma insulin-like growth factor (IGF)-I and IGF-binding protein-2 in Angus x Hereford steers independent of changes in nutritional intake. J Endocrinol 144:109-117, 1995
24. Fan J, Molina PE, Gelato MC, et al: Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 134:1685-1692, 1994
25. Dann MS, Lange MP, Jacobs LA: Insulinlike growth factor 1 production is inhibited in human sepsis. Arch Surg 123:1409-1414, 1988
26. Wolf M, Bohm S, Brand M, et al: Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 135:729-737, 1996
27. Saito H, Inoue T, Fukatsu K, et al: Growth hormone and the immune response to bacterial infection. Horm Res 45:50-54, 1996
28. Røkke O, Revhaug A, Østerud B, et al: Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: The effect of antibiotic administration. IN Bacterial Endotoxins. Pathophysiological Effects, Clinical Significance and Pharmacological Control, Levin J, Buller HR, ten Cate JW, et al (eds). Alan R Liss, New York, 1988, pp 247-262
29. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99-105, 1986
30. Boyum A: Separation of white blood cells. Nature 204:793, 1964
31. Hansen JB, Halvorsen DS, Haldorsen BC, et al: Retention of phagocytic functions in cryopreserved human monocytes. J Leukocyte Biol 57:235-241, 1995
32. Bassoe CF, Laerum OD, Solberg CO, et al: Phagocytosis of bacteria by human leukocytes measured by flow cytometry. Proc Soc Exp Biol Med 174:182-186, 1983
33. Rothe G, Oser A, Valet G: Dihydrorhodamine 123: A new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes. Naturwissenschaften 75:354-355, 1988
34. Inoue T, Saito H, Fukushima R, et al: Growth hormone and insulinlike growth factor I enhance host defense in a murine sepsis model. Arch Surg 130:1115-1122, 1995
35. Liao W, Rudling M, Angelin B: Contrasting effects of growth hormone and insulin-like growth factor I on the biological activities of endotoxin in the rat. Endocrinology 138:289-295, 1997
36. Douglas RG, Gluckman PD, Breier BH, et al: Effects of recombinant IGF-I on protein and glucose metabolism in rTNF-infused lambs. Am J Physiol 261:E606-612, 1991
37. Sakurai Y, Zhang XJ, Wolfe RR: Insulin-like growth factor-I and insulin reduce leucine flux and oxidation in conscious tumor necrosis factor-infused dogs. Surgery 117:305-313, 1995
38. Schini VB, Catovsky S, Schray Utz B, et al: Insulin-like growth factor I inhibits induction of nitric oxide synthase in vascular smooth muscle cells. Circ Res 74:24-32, 1994
39. Martel Pelletier J, Mineau F, Jolicoeur FC, et al: Modulation of TNFSR55 and TNFSR75 by cytokines and growth factors in human synovial fibroblasts. J Rheumatol 43 (Suppl):115-119, 1995
40. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 163:1177-1184, 1991
41. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664, 1987
42. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871, 1985
43. Hinshaw LB, Tekamp Olson P, Chang AC, et al: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 30:279-292, 1990
44. Stack AM, Saladino RA, Thompson C, et al: Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. Crit Care Med 23:1512-1518, 1995
45. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 21:318-327, 1993
46. Reinhart K, Wiegand Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733-742, 1996
47. Bjerknes R, Aarskog D: Priming of human polymorphonuclear neutrophilic leukocytes by insulin-like growth factor I: Increased phagocytic capacity, complement receptor expression, degranulation, and oxidative burst. J Clin Endocrinol Metab 80:1948-1955, 1995
48. Sara VR, Hall K: Insulin-like growth factors and their binding proteins. Physiol Rev 70:591-614, 1990
49. Oh Y, Muller HL, Neely EK, et al: New concepts in insulin-like growth factor receptor physiology. Growth Regul 3:113-123, 1993
50. Spadoni GL, Spagnoli A, Cianfarani S, et al: Enhancement by growth hormone of phorbol diester-stimulated respiratory burst in human polymorphonuclear leukocytes. Acta Endocrinol 121:589-594, 1991
51. Kelley KW, Arkins S, Li YM: Growth hormone, prolactin, and insulin-like growth factors: New jobs for old players. Brain Behav Immun 6:317-326, 1992
52. Weigent DA, Baxter JB, Wear WE, et al: Production of immunoreactive growth hormone by mononuclear leukocytes. FASEB J 2:2812-2818, 1988